SCHEMBL3550360

SCHEMBL3550360

O=C1CSC(c2ccccc2)N1CC(=S)Nc1cc(F)cc(F)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
GFER P55789 2/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
LMNA P02545 4/20 0.41
ALDH1A1 P00352 4/20 0.41
HPGD P15428 2/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
ALOX12 P18054 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ACHE P22303 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3549735 0.88 MEN1 (0.45) SMN1; SMN2MEN1KMT2AGFERCYP2C9
SCHEMBL3551478 0.74 MAPT (0.51) SMN1; SMN2MEN1KMT2AGFERCYP2C9
SCHEMBL3549397 0.74 TACR1 (0.47) SMN1; SMN2MEN1KMT2AGFERCYP2C9
SCHEMBL7204874 0.74 CYP2C9 (0.56) SMN1; SMN2MEN1KMT2ACYP2C9CYP2C19
SCHEMBL13501913 0.72 MEN1 (0.56) SMN1; SMN2MEN1KMT2AGFERCYP2C9
SCHEMBL3549503 0.72 CYP2C9 (0.61) SMN1; SMN2MEN1KMT2ACYP2C9CYP2C19
SCHEMBL8444032 0.70 PTGS1 (0.65) SMN1; SMN2MEN1KMT2ACYP2C9CYP2C19
SCHEMBL13502124 0.70 CYP2C9 (0.52) SMN1; SMN2MEN1KMT2ACYP2C9CYP2C19
SCHEMBL19306397 0.67 KMT2A (0.78) SMN1; SMN2MEN1KMT2ACYP2C9CYP2C19
SCHEMBL3558328 0.67 NPC1 (0.51) SMN1; SMN2NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143446-A1 THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, METHODS OF MAKING, AND USES THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2009-06-04 US claimed
EP-1692121-A1 THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, METHODS OF MAKING, AND USES THEREOF University of Tennessee Research Foundation (US) 2006-08-23 EP claimed
US-20060040998-A1 Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2006-02-23 US claimed
WO-2005049591-A1 THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, METHODS OF MAKING, AND USES THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2005-06-02 WO claimed
US-7662842-B2 Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents Ohio State Univesity Research Foundation (US) 2010-02-16 US disclosed
US-20090143446-A1 THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, METHODS OF MAKING, AND USES THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2009-06-04 US disclosed
WO-2008128179-A1 THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2008-10-23 WO disclosed
US-20080255213-A1 THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2008-10-16 US disclosed
EP-1926487-A2 THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS University of Tennessee Research Foundation (US) 2008-06-04 EP disclosed
WO-2008036067-A2 THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2008-03-27 WO disclosed
US-7307093-B2 Cancer, selectivity to prostate cancer cell lines, ovarian cancer cells THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2007-12-11 US disclosed
US-20070155807-A1 THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2007-07-05 US disclosed
EP-1723127-A2 ANALOGS EXHIBITING INHIBITION OF CELL PROLIFERATION, METHODS OF MAKING, AND USES THEREOF THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2006-11-22 EP disclosed
EP-1692121-A1 THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, METHODS OF MAKING, AND USES THEREOF University of Tennessee Research Foundation (US) 2006-08-23 EP disclosed
US-20060040998-A1 Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2006-02-23 US disclosed
US-20060014740-A1 Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof US GOVERNMENT - SECRETARY FOR THE ARMY 2006-01-19 US disclosed
WO-2005086638-A2 ANALOGS EXHIBITING INHIBITION OF CELL PROLIFERATION, METHODS OF MAKING, AND USES THEREOF THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2005-09-22 WO disclosed
WO-2005049591-A1 THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, METHODS OF MAKING, AND USES THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143446-A1 THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, METHODS OF MAKING, AND USES THEREOF NAT1, AADAC, PPARG SMN1; SMN2 4515/4885NPC1 1654/4885RAB9A 2420/4885
US-20060014740-A1 Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof MKI67, MCL1, API5 SMN1; SMN2 2776/4885NPC1 3077/4885RAB9A 3516/4885
US-20060040998-A1 Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof NAT1, AADAC, PPARG SMN1; SMN2 4515/4885NPC1 1654/4885RAB9A 2420/4885
US-20080255213-A1 THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS SRM, SAT1, SMS SMN1; SMN2 3622/4885NPC1 2465/4885RAB9A 3087/4885
US-20070155807-A1 THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS SRM, SAT1, SMS SMN1; SMN2 3464/4885NPC1 2439/4885RAB9A 2850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.